Luca Benatti

Luca Benatti
  • Luca is CEO of EryDel S.p.A. He has over 25 year experience in Pharma and Biotech. From 1985-1998 he held several positions in Farmitalia, Pharmacia&Upjohn.
  • He was Co-founder, CEO of Newron Pharmaceuticals, until May 2012. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound safinamide approved in EU for the treatment of Parkinson’s disease. During his tenure, Newron raised significant capital from international venture capital firms, and was listed at the Swiss stock exchange. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon, and in the acquisition of the UK biotech Company Hunter Fleming.
  • He is independent Board member at Newron Pharmaceuticals (SIX), Intercept Pharmaceuticals (Nasdaq), Chairman of the Strategic Advisory Board of Zambon, Vice President and member of the Board of Assobiotec. He has authored several scientific publications and holds numerous patents.
Share